New drug AZD4248 tested for kidney disease in first human trials
NCT ID NCT07024823
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This early-stage study tests the safety of a new drug called AZD4248 in healthy volunteers and people with chronic kidney disease and type 2 diabetes. Participants receive either the drug or a placebo, and researchers monitor side effects and how the drug moves through the body. The study also looks at whether people can reliably measure their kidney function at home using a simple test.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AZD4248
What this could lead to
If successful, this could pave the way for a new treatment option for chronic kidney disease in people with type 2 diabetes.
What could go wrong
This is an early Phase 1 trial focused on safety, so it's too soon to know if AZD4248 will work. The drug may cause side effects or prove ineffective in later studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGGlendale, California, 91206, United States
-
Research Site
RECRUITINGChicago, Illinois, 60643, United States
-
Research Site
ACTIVE_NOT_RECRUITINGAnn Arbor, Michigan, 48109, United States
-
Research Site
RECRUITINGSaint Paul, Minnesota, 55114, United States
-
Research Site
RECRUITINGSan Antonio, Texas, 78215, United States